Switch to DTG-3TC versus Continued 3- or 4-Drug ART

SALSA
Switch to DTG-3TC versus Continued 3- or 4-Drug Regimen

SALSA: Design

- **Design:** Open-label, non-inferiority trial in adults with suppressed HIV RNA while taking a 3- or 4-drug regimen, randomized to switch to fixed-dose dolutegravir-lamivudine (DTG-3TC) or continue baseline regimen

- **Inclusion Criteria**
  - Adults with suppressed HIV RNA ≥6 months
  - No history of virologic failure
  - No major NRTI resistance; no INSTI resistance
  - No Hepatitis B or C

- **Regimens**
  - Dolutegravir-lamivudine (50/300mg) daily
  - 3- or 4-drug baseline regimen

**Switch Group**

Dolutegravir-Lamivudine
(n = 246)

**Continue Baseline Regimen Group**

3- or 4-Drug Regimen
(n = 247)

Switch to DTG-3TC versus Continued 3- or 4-Drug Regimen
SALSA: 48 Week Results

Week 48 Virologic Response ITT-Exposed (Snapshot Analysis)

Conclusion: “Switching to dolutegravir-lamivudine was non-inferior to continuing current antiretroviral regimen for maintaining virologic suppression at Week 48 with no observed resistance, supporting the efficacy, good safety, and high barrier to resistance of dolutegravir-lamivudine.”
Acknowledgments

The **National HIV Curriculum** is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $1,021,448 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.